BioHarvest Sciences Inc（BHST）股票分析BHSTBioHarvest Sciences Inc

BioHarvest Sciences Inc. is a Canada-based botanical synthesis company. The Company leverages its technology platform to grow plant-based compounds, without the need to grow the underlying plant. It is leveraging its botanical synthesis technology to develop science-based therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking plant-based compounds, and as a creator of nutraceutical health and wellness products, which include dietary supplements. It delivers phytochemicals such as age-defying antioxidants and polyphenols used for wellness. Its product pipeline is focused on polyphenols, which include grape cells, olive cells, and pomegranate cells. Its process involves selecting the specific plant cells that can create the targeted ingredients. It offers VINIA, which is a nutraceutical containing the entire matrix of polyphenols contained in red grapes, including Piceid resveratrol. It operates in the Healthcare sector.

Bioharvest Sciences Inc is not a good buy right now due to a current price of $1.84, a very low RSI of 19.396 indicating oversold conditions, and a significant year-to-date decline of 64.68%. The company has reported consistent net losses, including a Q1 2026 loss of $2.6 million, which raises concerns about its financial health. The main risk is the forward P/E ratio of 153.85, suggesting that the stock is overvalued relative to its earnings potential.